FTC approves final settlement on generic drug divestiture

The Federal Trade Commission gave final approval to a settlement that satisfies its concerns that Impax Laboratories Inc.’s purchase of CorePharma would be anticompetitive.

Under the agreement the companies will sell...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:
Email: customerservices@mlex.com

FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch